Literature DB >> 11177732

Recent Advances in Schistosomiasis.

G. Richard Olds1, Srinivasan Dasarathy.   

Abstract

Schistosomiasis is a major parasitic disease, affecting nearly 200 million persons, worldwide. Major advances in our knowledge-in terms of pathogenesis, improved diagnosis, therapeutics (both drugs and strategies), and morbidity assessment-now make schistosomiasis a curable, often preventable disease. In contrast to most other illnesses, most schistosomiasis pathology appears to be reversible over time. For the future, several promising vaccine candidates are already in phase-I or phase-II testing. On the other hand, the range of this disease has been increasing, as water resources are developed in several newly industrialized countries and much of schistosomiasis in sub-Saharan Africa remains largely untreated.

Entities:  

Year:  2001        PMID: 11177732     DOI: 10.1007/s11908-001-0060-1

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  47 in total

1.  Experimental models of immunization against schistosomes: lessons for vaccine development.

Authors:  S L James
Journal:  Immunol Invest       Date:  1992-08       Impact factor: 3.657

2.  Sex-dependent neutralizing humoral response to Schistosoma mansoni 28GST antigen in infected human populations.

Authors:  F Remoué; F Rogerie; M C Gallissot; H L Guyatt; J L Neyrinck; M M Diakkhate; M Niang; A E Butterworth; C Auriault; A Capron; G Riveau
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  Comparison of the direct faecal smear and two thick smear techniques for the diagnosis of intestinal parasitic infections.

Authors:  D Engels; S Nahimana; B Gryseels
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Sep-Oct       Impact factor: 2.184

Review 4.  Immunologic basis of disease and disease regulation in schistosomiasis.

Authors:  A W Cheever; G S Yap
Journal:  Chem Immunol       Date:  1997

5.  Paramyosin is a major target of the human IgA response against Schistosoma japonicum.

Authors:  M G Hernandez; J C Hafalla; L P Acosta; F F Aligui; G D Aligui; B L Ramirez; D W Dunne; M L Santiago
Journal:  Parasite Immunol       Date:  1999-12       Impact factor: 2.280

Review 6.  Antischistosomal drugs: past, present ... and future?

Authors:  D Cioli; L Pica-Mattoccia; S Archer
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

7.  Morbidity due to schistosomiasis japonica in the People's Republic of China.

Authors:  P M Wiest; G Wu; S Zhang; J Yuan; P A Peters; S T McGarvey; M Tso; R Olveda; G R Olds
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Jan-Feb       Impact factor: 2.184

8.  Evidence for an improvement in cognitive function following treatment of Schistosoma japonicum infection in Chinese primary schoolchildren.

Authors:  C Nokes; S T McGarvey; L Shiue; G Wu; H Wu; D A Bundy; G R Olds
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

Review 9.  Immunity and morbidity in schistosomiasis japonicum infection.

Authors:  G R Olds; R Olveda; G Wu; P Wiest; S McGarvey; G Aligui; S Zhang; B Ramirez; B Daniel; P Peters; R Romulo; P Fevidal; W Tiu; J Yuan; E Domingo; B Blas
Journal:  Am J Trop Med Hyg       Date:  1996-11       Impact factor: 2.345

10.  Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59.

Authors:  M Parizade; R Arnon; P J Lachmann; Z Fishelson
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  2 in total

1.  Sedum sarmentosum Total Flavonoids Alleviate Schistosomiasis-Induced Liver Fibrosis by Altering TGF-β1 and Smad7 Expression.

Authors:  Peng-Chun Yang; Wei-Zhe Bai; Jing Wang; Cai-Hua Yan; Wei-Feng Huang; Shi-Zhu Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2020-11-26       Impact factor: 2.629

2.  New insight into the antifibrotic effects of praziquantel on mice in infection with Schistosoma japonicum.

Authors:  Yue-Jin Liang; Jie Luo; Quan Yuan; Dan Zheng; Ya-Ping Liu; Lei Shi; Ying Zhou; Ai-Ling Chen; Yong-Ya Ren; Ke-Yi Sun; Yan Sun; Yong Wang; Zhao-Song Zhang
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.